CSL Stock Crashes 5%: $150B ASX BioTech Giant Risks Earnings Miss
Поделиться:
CSL Ltd (ASX:CSL) shares plunged 5% in early trade today to A$171.39 (down A$8.98), extending a brutal multi-year rout that has already wiped 39% off the stock since early 2025 highs.
The biotech powerhouse, once Australia's ultimate blue-chip growth machine, now trades at levels not seen since mid-2021, as investors pile into defensive positioning ahead of tomorrow's critical half-year FY26 earnings.
Earnings Fears Ignite Panic Selloff
Wall Street and local brokers whisper revenue and EPS misses loom large, with plasma collection volumes flatlining and US flu vaccine uptake cratering to historic lows (down 20%+ YoY per CDC data). Seqirus margins, hit by manufacturing inefficiencies and pricing pressure – could drag overall guidance, while CSL Behring's immunoglobulin launches face reimbursement hurdles in Europe. Consensus expects A$7.8B revenue and A$2.7B profit, but even inline results may disappoint after 2025's A$500M cost-cutting bombshell failed to stem the bleed.
Options flow shows heavy put buying at the A$240 strike, signaling traders brace for a post-earnings gap lower to A$220 support. Volume surged to 1M+ shares vs. 920K average, with day range A$171-A$184 confirming capitulation.
From ASX Royalty to Beaten-Down Value Trap?
CSL built a A$150B empire collecting blood plasma globally (world #1), crafting rare immunoglobulins, antivenoms (saving snakebite victims yearly), and blockbuster flu shots via Seqirus – the planet's largest influenza vaccine maker. Vifor adds iron deficiency treatments, but delayed spinoff drama and China regulatory snarls have eroded the moat.
Analysts cling to A$260-A$300 targets (50%+ upside), citing plasma supply ramping to 45M litres annually by 2028 and gene therapy moonshots. Yet P/E compression to 19.5x forward (from 45x peaks) reflects growth reset from 15% to 8-10% CAGR through 2028.
2025's carnage: US vaccination apathy (post-COVID fatigue), factory overruns costing A$300M+, Behring pipeline delays – all colliding as rates rose. 50-day MA A$177, 200-day A$213 both breached.
Chart Breakdown and Key Catalysts
Daily chart screams bear flag targeting A$215 if A$240 breaks. RSI at 35 (oversold) hints bounce potential, but MACD death cross warns deeper pain. Volatility spikes 50% above norms.
Watchlist:
H1 revenue/EPS vs. A$7.8B/A$2.34 expectations
FY26–28 guidance refresh (plasma + vaccines outlook)
Spinoff timeline clarity
Cost program update (A$500M savings trajectory)
A beat restores faith in CSL's irreplaceable plasma monopoly; another miss risks A$200 capitulation. Australia's pharma titan fights for redemption.
В этой новости
Фонды
Поделиться:
В этой новости
Фонды
Поделиться:
Читать больше
Monday Stock Drops 22%: Q4 Earnings Report Cuts $6B Market Cap
Anthropic India Expansion Sparks Critical Trademark Clash with Local Software Firm
CSL Stock Crashes 5%: $150B ASX BioTech Giant Risks Earnings Miss
Поделиться:
CSL Ltd (ASX:CSL) shares plunged 5% in early trade today to A$171.39 (down A$8.98), extending a brutal multi-year rout that has already wiped 39% off the stock since early 2025 highs.
The biotech powerhouse, once Australia's ultimate blue-chip growth machine, now trades at levels not seen since mid-2021, as investors pile into defensive positioning ahead of tomorrow's critical half-year FY26 earnings.
Earnings Fears Ignite Panic Selloff
Wall Street and local brokers whisper revenue and EPS misses loom large, with plasma collection volumes flatlining and US flu vaccine uptake cratering to historic lows (down 20%+ YoY per CDC data). Seqirus margins, hit by manufacturing inefficiencies and pricing pressure – could drag overall guidance, while CSL Behring's immunoglobulin launches face reimbursement hurdles in Europe. Consensus expects A$7.8B revenue and A$2.7B profit, but even inline results may disappoint after 2025's A$500M cost-cutting bombshell failed to stem the bleed.
Options flow shows heavy put buying at the A$240 strike, signaling traders brace for a post-earnings gap lower to A$220 support. Volume surged to 1M+ shares vs. 920K average, with day range A$171-A$184 confirming capitulation.
From ASX Royalty to Beaten-Down Value Trap?
CSL built a A$150B empire collecting blood plasma globally (world #1), crafting rare immunoglobulins, antivenoms (saving snakebite victims yearly), and blockbuster flu shots via Seqirus – the planet's largest influenza vaccine maker. Vifor adds iron deficiency treatments, but delayed spinoff drama and China regulatory snarls have eroded the moat.
Analysts cling to A$260-A$300 targets (50%+ upside), citing plasma supply ramping to 45M litres annually by 2028 and gene therapy moonshots. Yet P/E compression to 19.5x forward (from 45x peaks) reflects growth reset from 15% to 8-10% CAGR through 2028.
2025's carnage: US vaccination apathy (post-COVID fatigue), factory overruns costing A$300M+, Behring pipeline delays – all colliding as rates rose. 50-day MA A$177, 200-day A$213 both breached.
Chart Breakdown and Key Catalysts
Daily chart screams bear flag targeting A$215 if A$240 breaks. RSI at 35 (oversold) hints bounce potential, but MACD death cross warns deeper pain. Volatility spikes 50% above norms.
Watchlist:
H1 revenue/EPS vs. A$7.8B/A$2.34 expectations
FY26–28 guidance refresh (plasma + vaccines outlook)
Spinoff timeline clarity
Cost program update (A$500M savings trajectory)
A beat restores faith in CSL's irreplaceable plasma monopoly; another miss risks A$200 capitulation. Australia's pharma titan fights for redemption.
В этой новости
Фонды
Поделиться:
В этой новости
Фонды
Поделиться:
Читать больше
Monday Stock Drops 22%: Q4 Earnings Report Cuts $6B Market Cap